From established to emerging markets: Integrating anti-counterfeiting solutions for every need

Pharmaceutical counterfeiting is a globally recognized problem, but it does not look the same everywhere. Research shows that in certain global markets, reports of stolen or counterfeit medicines have risen by as much as 374%. At the same time, established high-growth markets face a threat in counterfeiters who exploit gaps in otherwise robust systems. Packaging sits at the heart of this challenge in every region, but what it needs to do varies enormously depending on where in the world it is being used.

Treating anti-counterfeiting as a single global standard, applied uniformly regardless of geography, risks under-protecting high-risk markets while overengineering low-risk ones. The smarter approach starts with understanding how risk, regulation and infrastructure differ from one region to the next and building packaging security accordingly.

Established markets: from compliance to optimization
In the EU and US, regulatory groundwork is largely in place. The Falsified Medicines Directive and the Drug Supply Chain Security Act have made serialisation and tamper-evident features a fundamental requirement for secondary pharma packaging. Track and trace infrastructure is mature, scanning is routine, and most stakeholders along the supply chain know what compliance looks like.

This changes the dynamic of anti-counterfeiting. Pharmaceutical companies operating in established markets do not need to ask whether they need serialization, but how to extract more value from it. The focus moves from meeting the minimum regulatory bar to integrating security features into wider operational goals: faster line speeds, fewer changeovers, better data capture, and packaging that supports automation, rather than slowing it down.

This is where efficiency and scalability become as important as the security feature itself. A solution that ticks the regulatory boxes but disrupts production economics is not truly fit for purpose in a market where margins and throughput are under constant pressure. The opportunity in established markets lies in making compliance work harder, not in reinventing it.

Emerging markets: higher exposure, different challenges
Emerging markets present a different challenge entirely. Supply chains are often more fragmented, passing through more intermediaries or suppliers with less consistent oversight at each stage. Regulatory enforcement, where it exists on paper, can be patchy in practice. The result is a higher level of exposure to falsified medicines, and a patient population that often has no reliable way to verify what they are taking before they take it.

In this context, the priority is visibility and robustness. Packaging needs to do more of the verification work itself, because the surrounding infrastructure cannot always be relied upon to do it. Overt features that allow immediate, tool-free verification carry a lot of weight here, since a patient, pharmacist or distributor without access to scanning technology still needs a way to judge authenticity at a glance.

This does not mean emerging markets are left with cruder or more basic solutions. It means the combination of features needs to be weighted differently, leaning more heavily on robust physical security that functions independently of digital or institutional infrastructure, while still building toward the track and trace capability that will eventually arrive.

Packaging as a layered security system
The common link between both market categories is that no single feature, however advanced, is enough on its own. Pharma packaging security works best as a layered system, where different types of protection combine to add extra dimensions.

Overt features, such as tamper-evident seals, holograms and specialist inks, are visible to the eye and enable instant verification without the need for specialist equipment. They build trust at the point of use and are often the first line of defence, particularly where infrastructure for deeper verification is limited.

Covert features, meanwhile, sit beneath the surface. They are detectable only with specific tools or trained inspection. Microtext, security patterns and similar techniques enable customs officials, brand protection teams and other experts to authenticate products with a level of confidence that visual inspection alone cannot provide.

Forensic features go further still, requiring laboratory-level analysis to confirm. These are typically reserved for the highest-risk products and the most determined investigations, where definitive proof is required.

Digital solutions, including QR codes, NFC (Near-Field Communication) and RFID (Radio Frequency Identification), add another dimension altogether. They bring traceability through the supply chain, direct engagement with patients, and data that can inform recalls, adherence programmes and broader supply chain intelligence.

The right combination of these layers depends on the market, the product and the risk profile in question. A high-value injectable biologic moving through a fragmented supply chain may warrant a denser combination of overt and covert features than a well-established generic moving through a tightly regulated, serialised market.

From protection to intelligence
As these technologies mature, their value is extending beyond pure anti-counterfeiting.

The same digital layer that authenticates a product can also generate supply chain visibility, support patient interaction, and provide data that feeds back into commercial and safety decisions. Anti-counterfeiting and broader supply chain intelligence are converging. Packaging is increasingly the point where that convergence happens.

There is no universal anti-counterfeiting solution, and pursuing one risks either overspending in low-risk markets or under-protecting high-risk ones. What works more effectively is flexibility: understanding the regulatory maturity, supply chain structure and risk profile of each market, and combining physical and digital technologies accordingly.

For pharmaceutical companies operating across multiple geographies at once, this is rarely something to navigate alone. It requires a packaging partner, like MM Pharma and Healthcare Packaging, with the technical range to deploy the full spectrum of security features, and the regional understanding to know which combination actually fits the market in front of them.